Overview

Phase 1 Study With Sorafenib and Sirolimus

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.
Phase:
Phase 1
Details
Lead Sponsor:
Radboud University
Collaborator:
Bayer
Treatments:
Everolimus
Sirolimus
Sorafenib